Amitkumar Mehta, MD, discusses the role of parsaclisib and how it fits into the treatment landscape of relapsed/refractory mantle cell lymphoma.
Amitkumar Mehta, MD, associate professor, and director of lymphoma and the CAR T-cell therapy program at the University of Alabama at Birmingham School of Medicine, spoke with CancerNetwork® at the 2021 American Society of Hematology Annual Meeting about data from the phase 2 CITADEL-205 study (NCT03235544), investigating parsaclisib as a treatment for patients with relapsed/refractory mantle cell lymphoma (MCL).
Mehta discussed the data and safety profile associated with parsaclisib in the context of other existing treatment options for MCL, including ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa).
As I was mentioning, in the relapsed/refractory setting in [MCL], we have BTK inhibitors [such as] ibrutinib, acalabrutinib, and zanubrutinib. I feel that parsaclisib has a place in relapsed/refractory [MCL], because if you look at the response rate, they're almost similar to initial ibrutinib data. I see that it is very active and it’s a good alternative to the BTK inhibitor.
[There are] patients who cannot tolerate the BTK inhibitors. We all know that CAR [T-cell therapy] is not universally available for all patients [and] it having specific toxicities, especially cytokine release syndrome, as well as immune effector cell-associated neurotoxicity syndrome] or neurotoxicity syndrome. Of course, cytopenias and hypogammaglobulinemia can happen with CAR T, [as well]. In that setting, I would say that parsaclisib has a space [in MCL] because it is an oral agent, relatively well tolerated, and has good activity in [this disease].
Mehta A, Trněný M, Walewski J, et al. Efficacy and safety of parsaclisib in patients with relapsed or refractory mantle cell lymphoma not previously treated with a BTK inhibitor: Primary analysis from a phase 2 study (CITADEL-205) Presented at: 63rd ASH Annual Meeting; December 11, 2021; Atlanta, GA. Abstract 382.